Wednesday, August 11, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)

A Conversation with the Investigators: Perspectives on the Management of Head and Neck Cancer

A Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual Meeting

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Wednesday, August 11th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET


Barbara Burtness, MD
Professor of Medicine
Yale School of Medicine
Co-Leader, Developmental Therapeutics Program
Director, Yale Head and Neck SPORE
Yale Cancer Center
New Haven, Connecticut

Ezra Cohen, MD
Professor of Medicine
Chief, Division of Hematology-Oncology
Associate Director, Clinical Science
Moores Cancer Center at UC San Diego Health
La Jolla, California

Robert L Ferris, MD, PhD
Director, UPMC Hillman Cancer Center
Hillman Professor of Oncology
Associate Vice Chancellor for Cancer Research
Co-Director, Tumor Microenvironment Center
Professor, Departments of Otolaryngology, Immunology, and Radiation Oncology
Pittsburgh, Pennsylvania

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

This activity is supported by an educational grant from Merck.

Topics for discussion

  • Risk factors (eg, tobacco/alcohol consumption, exposure to environmental pollutants) for the development of head and neck cancer
  • Molecular biomarkers and key pathways in the development and progression of squamous cell carcinoma of the head and neck (SCCHN); diagnosis, screening and prevention strategies
  • Clinical factors (eg, preexisting comorbidities, performance status and pathologic features) to consider when designing therapeutic plans for patients with SCCHN
  • Role of the human papillomavirus (HPV) in the development of head and neck cancer; HPV status and the use of immune checkpoint inhibitors for SCCHN
  • Factors in the selection of therapy for patients with SCCHN, including prior treatment, time since completion of definitive treatment, age, symptomatology, extent of metastases and PD-L1 expression
  • Clinical role of concurrent and/or induction chemotherapy with radiation therapy for patients presenting with locoregional SCCHN
  • Published research data with and current clinical role of cetuximab in the treatment of localized, recurrent or metastatic SCCHN; role of EGFR-targeted therapies in the era of immunotherapy
  • Prevalence and clinical implications of EGFR mutations in progressive SCCHN; recent FDA approval of a new dosage regimen for cetuximab
  • Spectrum, frequency and severity of toxicities observed with cetuximab in combination with platinum-based chemotherapy; strategies to mitigate side effects
  • Clinical utility of testing for microsatellite instability and PD-L1 status; use of the PD-L1 tumor proportion score and/or the combined positive score (CPS) for patients with SCCHN and similarities and differences among the available PD-L1 assays
  • Key efficacy and safety results from the Phase III KEYNOTE-048 trial supporting the FDA approval of pembrolizumab as first-line therapy for recurrent or metastatic SCCHN
  • Optimal management of PD-L1-positive SCCHN in patients who experience disease progression on first-line pembrolizumab administered alone or in combination with chemotherapy
  • Research databases supporting the use of immune checkpoint inhibitors for SCCHN; identification of patients who are not eligible
  • Mechanism of action and emerging trial results with camrelizumab alone or in combination with chemotherapy for recurrent or metastatic head and neck cancer
  • Results from the Phase III KESTREL and EAGLE trials comparing the anti-PD-L1 antibody durvalumab with or without tremelimumab to standard treatment for patients with recurrent or metastatic SCCHN
  • Biologic rationale for the investigation of bempegaldesleukin in combination with pembrolizumab in a Phase II/III trial for patients with head and neck cancer with a PD-L1 CPS of 1 or higher
  • Updated results from the Phase III JAVELIN Head and Neck 100 study evaluating avelumab in addition to chemoradiation therapy versus chemoradiation therapy alone for untreated locally advanced SCCHN; recommendations to terminate the study
  • Recognition, incidence, monitoring and optimal management of immune-related adverse events in patients receiving immune checkpoint inhibitor therapy
  • Mechanisms of resistance to EGFR inhibition and immune checkpoint inhibition in SCCHN
  • Mechanism of action of tipifarnib and published data with this agent in the cohort of patients with HRAS-mutated recurrent and/or metastatic SCCHN after disease progression on platinum-based chemotherapy in the Phase II RUN-HN trial; recent FDA breakthrough therapy designation for tipifarnib
  • Roles of entrectinib and larotrectinib in therapy for patients with salivary gland carcinoma with NTRK gene fusions
  • Mechanism of action of xevinapant and rationale for ongoing investigation in the Phase III TrilynX study for patients with previously untreated, high-risk locally advanced SCCHN

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of head and neck cancer.

Learning Objectives

  • Consider emerging research information and available guideline recommendations in the development of a genomic testing algorithm to personalize therapy with novel immunotherapeutic and targeted regimens for patients with head and neck cancer.
  • Appreciate available Phase III findings supporting the FDA approval of pembrolizumab as first-line therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), in combination with platinum-based chemotherapy or as monotherapy for those with PD-L1-positive tumors, and consider the implications of this information for clinical practice.
  • Appraise clinical trial data documenting the efficacy and safety of immune checkpoint inhibitors alone or in combination with systemic or targeted therapies for recurrent or metastatic SCCHN in order to optimally sequence approved agents for patients with progressive disease.
  • Recall the biologic rationale for dual immune checkpoint inhibitor therapy or for combining immune checkpoint inhibitors with chemotherapy, radiation therapy, chemoradiation therapy and/or surgery in the multimodality management of SCCHN, and evaluate ongoing research investigating the potential benefit of these combinations in the locally advanced, recurrent or metastatic disease settings.
  • Design and implement a plan of care to recognize and manage immune-related adverse events associated with recently approved and emerging immune checkpoint inhibitor regimens and the side effects of other novel targeted regimens to support quality of life and continuation of therapy.
  • Recognize the recent FDA approval of a new dosage schedule with cetuximab for SCCHN, and identify patients who are appropriate candidates for this new regimen.
  • Consider the clinical relevance of NTRK gene fusions in salivary gland carcinoma, and appreciate available clinical research evidence with and FDA endorsements of the agents larotrectinib and entrectinib for patients with NTRK fusions in order to appropriately select therapy.
  • Design an optimal approach to the clinical care of patients with localized, locally advanced, recurrent or metastatic SCCHN, considering the implications of symptomatology, targetable genetic mutations and other factors.
  • Appreciate the biologic rationale for and available data with novel immunotherapeutic approaches for SCCHN to facilitate their introduction into clinical practice.
  • Review the oncogenic pathways (eg, PD-1/PD-L1, HRAS, NTRK, inhibitors of apoptosis proteins) that mediate the pathogenesis of tumors in unique patient subsets, and recall published and emerging data with commercially available and experimental agents exploiting these targets.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for SCCHN, and counsel appropriate patients about availability and participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

Dr BurtnessAdvisory Committee: AstraZeneca Pharmaceuticals LP, Chinook Therapeutics, Cue Biopharma, Debiopharm Group, IO Biotech, Ipsen Biopharmaceuticals Inc, Kura Oncology, MacroGenics Inc, Merck, Nanobiotix, Nuvelution Pharma Inc, Rakuten Medical Inc; Consulting Agreements (Grant/Research/Clinical Trial Support): Bristol-Myers Squibb Company, Cue Biopharma, Merck. Dr CohenBoard of Directors: PsiOxus; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Eisai Inc, Gilead Sciences Inc, Janssen Biotech Inc, Kinnate Biopharma, Merck, Merck Sharp & Dohme Corp, Mirati Therapeutics, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc; Ownership Interest: Shares held in Kinnate Biopharma and Primmune Therapeutics. Dr FerrisAdvisory Committee: Bristol-Myers Squibb Company, EMD Serono Inc, Instil Bio Inc, Lifescience Dynamics Ltd, MacroGenics Inc, Merck, Numab, Oncocyte, Pfizer Inc, Rakuten Medical; Consulting Agreements: Bicara Therapeutics, Chinook Therapeutics, F Hoffmann-La Roche Ltd, Genocea, Kowa Research Institute Inc, Mirati Therapeutics, Novasenta, Sanofi Genzyme, Zymeworks; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Novasenta, Tesaro, A GSK Company; Stock: Novasenta.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by an educational grant from Merck.